Methylnaltrexone: MNTX

Drugs in R and D

Volumn 7, Issue 6, 2006, Pages 374-378

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; NALOXONE; OPIATE ANTAGONIST; PLACEBO;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; CLINICAL TRIAL; CONSTIPATION; COUGHING; DRUG MECHANISM; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNITED STATES; URINE RETENTION; UROGENITAL TRACT DISEASE; VOMITING;

CLINICAL TRIALS; COLIC; CONSTIPATION; FLATULENCE; HUMANS; INJECTIONS, INTRAVENOUS; NALTREXONE; NARCOTIC ANTAGONISTS; QUATERNARY AMMONIUM COMPOUNDS; TREATMENT OUTCOME;

EID: 33750588519     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200607060-00006     Document Type: Review

References (16)

1. Wyeth Pharmaceuticals, Progenics Pharmaceuticals Inc. Wyeth and Progenics Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Methylnaltrexone; Methylnaltrexone in Late-Stage Clinical Development for Opioid-Induced Constipation and Post-Operative Bowel Dysfunction. Media Release: 23 Dec 2005. Available from URL: http://www.wyeth.com
2. Progenics Pharmaceuticals Inc. Progenics Acquires Methylnaltrexone Rights from Licensors and Plans to File Shelf Registrations. Media Release: 23 Dec 2005. Available from URL: http://www.progenics.com
3. Progenics Pharmaceuticals Inc. Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock. Media Release: 1 Apr 2005. Available from URL: http://www.progenics.com
4. Progenics Pharmaceuticals Inc. Progenics Announces Positive Top-Line Results from Second Pivotal Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation; All Primary and Secondary Efficacy Endpoints Were Highly Statistically Significant. Media Release: 15 Feb 2006. Available from URL: http://www.progenics.com
5. Progenics Pharmaceuticals Inc. Progenics Initiates Second Phase 3 Clinical Trial of Methylnaltrexone in Opioid-Induced Constipation. Media Release: 13 Jan 2004. Available from URL: http://www.progenics.com
6. Progenics Pharmaceuticals Inc. Progenics Achieves Enrollment Target in Second Pivotal Phase 3 Clinical Trial of Methylnaltrexone for Opioid-Induced Constipation. Media Release: 30 Sep 2005. Available from URL: http://www.progenics.com
7. Progenics Pharmaceuticals Inc. CORRECTING and REPLACING Progenics Announces Positive Top-Line Results from Pivotal Phase 3 Clinical Trial of methylnaltrexone in Opioid-Induced Constipation. Media Release: 10 Mar 2005. Available from URL: http://www.progenics.com
8. Progenics Pharmaceuticals Inc. Progenics Achieves Enrollment Target in Pivotal Phase 3 Clinical Trial of Methylnaltrexone for Opioid-Induced Constipation. Media Release: 3 Dec 2004. Available from URL: http://www.progenics.com
9. Wyeth Pharmaceuticals, Progenics Pharmaceuticals. Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus. Media Release: 17 Jul 2006. Available from URL: http://www.wyeth.com
10. Progenics Pharmaceuticals Inc. Progenics Announces Positive Top-Line Results from Phase 2 Clinical Trial of methylnaltrexone in Post-Operative Bowel Dysfunction. Media Release: 20 Jan 2005. Available from URL: http://www.progenics.com
11. Progenics Pharmaceuticals Inc. Progenics Pharmaceuticals Successfully Completes Two, Phase 1 Clinical Studies of Oral Methylnaltrexone. Media Release: 25 May 2004. Available from URL: http://www.progenics.com
12. Progenics Pharmaceuticals Inc. Progenics Initiates Methylnaltrexone Phase-3 Clinical Program for Opioid-Induced Constipation; Positive Phase-2 Trial in Hospice Patients Provides Basis for Pivotal Study. Media Release: 20 Dec 2002. Available from URL: http://www.progenics.com
13. Progenics Pharmaceuticals Inc. Progenics Reports Methylnaltrexone Activity in Reversing Opioid-Induced Urinary Retention. Media Release: 10 Oct 2003. Available from URL: http://www.progenics.com
14. Progenics Pharmaceuticals Inc. Progenics initiates phase 2 clinical trial of methylnaltrexone to treat post-operative ileus. Media Release: 13 May 2003. Available from URL: http://www.progenics.com
15. Yuan C-S, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA: the Journal of the American Medical Association 283: 367-372, 19 Jan 2000
16. Progenics Pharmaceuticals Inc. Progenics announces results from methylnaltrexone phase 2 clinical trial in opioid-induced constipation. Media Release: 30 Apr 2003. Available from URL: http://www.progenics.com